Bandingkan Harga & Kinerja Fast Food Indonesia Tbk. (FAST) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Fast Food Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Fast Food Indonesia Tbk. diperdagangkan di Rp440 (kapitalisasi pasar 2,02 T, volume 24 jam 5,71 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Fast Food Indonesia Tbk. jauh lebih besar — sekitar 19,3× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| FAST | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 2,02 T | 104,4 M |
Volume | 5,71 jt | — |
Lot | 57,09 rb | — |
Perputaran | 2,52 M | — |
Harga Rata-rata | 441,35 | — |
Nilai Transaksi | 2,52 M | — |
Harga Ekuilibrium Indikatif | 440 | — |
Volume Ekuilibrium Indikatif | 1,11 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Fast Food Indonesia Tbk.
PT. Fast Food Indonesia Tbk is a company founded in 1978 by the Gelael Group and the exclusive KFC franchise holder in Indonesia. The first KFC outlet opened in October 1979 at Jl. Melawai, Jakarta proved to be successful and paved the way for the opening of more additional outlets in Jakarta. The Company expanded its regional coverage to include other major cities in Indonesia and because of its success in building KFC brand image for the past 20 years of operation, KFC became the country’s dominant fast food market leader.
Selengkapnya di halaman FAST →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
